'Sleeping Beauty' Puts U of M's Licensing Revenue at No. 2 among Big Ten
A recent Association of University Technology Managers survey ranked the U of M second among Big Ten schools when it comes to licensing revenue.
The boost in revenue was almost entirely thanks to a licensing deal for a cancer treatment Texas-based M.D. Anderson developed based on University of Minnesota research, the school told Business Journal sister publication Columbus Business First.
The treatment is tied into U of M's research into "Sleeping Beauty," a gene that is generally inactive (or sleeping) but can be restarted for therapy purposes. M.D. Anderson's treatment uses patients' immune systems to attack tumors.
Read the full story in the Minneapolis/St. Paul Business Journal.